Literature DB >> 12849067

High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation?

Danielle Burger1, Jean-Michel Dayer.   

Abstract

The etiology of chronic immuno-inflammatory diseases including rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus erythematosus (SLE), and atherosclerosis is far from being elucidated. It is generally accepted that multiple factors are involved in the development of such pathologies, including factors of genetic susceptibility that interact in complex ways with diverse environmental factors, i.e. gender, nutrition, environment, etc. Furthermore, infection has often been pinpointed as playing a causal role. However, no distinctive pattern has yet emerged from the tremendous number of compiled results that would provide a generally acceptable hypothesis of the etiology of immuno-inflammatory diseases, and the possibility of a persistent antigenic stimulus arising from an infection cannot be confirmed or refuted. At the cellular level, chronic inflammation is characterized by the infiltration of immuno-inflammatory cells into the target tissue, which mostly precedes tissue damage. At the inflammatory site, monocytes and T lymphocytes are in close proximity. We have demonstrated that contact-mediated activation of monocytes by stimulated T lymphocytes is a major stimulus triggering the production of large amounts of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) whose importance in chronic inflammation is well known. We recently established that high-density lipolipoprotein (HDL)-associated apolipoprotein (apo) A-I is a specific inhibitor of cytokine production in monocyte-macrophages upon contact with stimulated T cells. HDL-associated apo A-I is a negative acute-phase protein, i.e. a protein whose level is lowered by more than 25% during the acute phase. This review aims at highlighting the fact that HDL-associated apo A-I might play the role of a constitutive anti-inflammatory factor. The decrease of plasma levels of HDL-associated apo A-I upon acute inflammation may be a sign of the possible development of chronic inflammation, i.e. individuals presenting with risk factors might develop chronic inflammatory diseases after infection. We thus hypothesize that HDL-associated apo A-I might be the missing link between infection and chronic inflammation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12849067     DOI: 10.1016/s1568-9972(01)00018-0

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  62 in total

Review 1.  Anti-oxidant properties of high-density lipoprotein and atherosclerosis.

Authors:  Eugene A Podrez
Journal:  Clin Exp Pharmacol Physiol       Date:  2010-03-30       Impact factor: 2.557

2.  Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis.

Authors:  V P van Halm; J C van Denderen; M J L Peters; J W R Twisk; M van der Paardt; I E van der Horst-Bruinsma; R J van de Stadt; M H M T de Koning; B A C Dijkmans; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2006-04-27       Impact factor: 19.103

Review 3.  Role of apolipoproteins in gammadelta and NKT cell-mediated innate immunity.

Authors:  Eric Champagne; Laurent O Martinez; Pierre Vantourout; Xavier Collet; Ronald Barbaras
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

4.  Common variants at the promoter region of the APOM confer a risk of rheumatoid arthritis.

Authors:  Hae Jin Hu; Eun Heui Jin; Seon Hee Yim; So Young Yang; Seung Hyun Jung; Seung Hun Shin; Wan Uk Kim; Seung Cheol Shim; Tai Gyu Kim; Yeun Jun Chung
Journal:  Exp Mol Med       Date:  2011-11-30       Impact factor: 8.718

Review 5.  Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis.

Authors:  V F Azevedo; R Pecoits-Filho
Journal:  Rheumatol Int       Date:  2010-03-27       Impact factor: 2.631

6.  Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis.

Authors:  C Trocmé; H Marotte; A Baillet; B Pallot-Prades; J Garin; L Grange; P Miossec; J Tebib; F Berger; M J Nissen; R Juvin; F Morel; P Gaudin
Journal:  Ann Rheum Dis       Date:  2008-07-29       Impact factor: 19.103

7.  Apolipoprotein A-IV inhibits experimental colitis.

Authors:  Thorsten Vowinkel; Mikiji Mori; Christian F Krieglstein; Janice Russell; Fumito Saijo; Sulaiman Bharwani; Richard H Turnage; W Sean Davidson; Patrick Tso; D Neil Granger; Theodore J Kalogeris
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

8.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.

Authors:  Steffen Walter; Toni Weinschenk; Arnulf Stenzl; Romuald Zdrojowy; Anna Pluzanska; Cezary Szczylik; Michael Staehler; Wolfram Brugger; Pierre-Yves Dietrich; Regina Mendrzyk; Norbert Hilf; Oliver Schoor; Jens Fritsche; Andrea Mahr; Dominik Maurer; Verona Vass; Claudia Trautwein; Peter Lewandrowski; Christian Flohr; Heike Pohla; Janusz J Stanczak; Vincenzo Bronte; Susanna Mandruzzato; Tilo Biedermann; Graham Pawelec; Evelyna Derhovanessian; Hisakazu Yamagishi; Tsuneharu Miki; Fumiya Hongo; Natsuki Takaha; Kosei Hirakawa; Hiroaki Tanaka; Stefan Stevanovic; Jürgen Frisch; Andrea Mayer-Mokler; Alexandra Kirner; Hans-Georg Rammensee; Carsten Reinhardt; Harpreet Singh-Jasuja
Journal:  Nat Med       Date:  2012-07-29       Impact factor: 53.440

9.  Comparison of serum apolipoprotein A-I between Chinese multiple sclerosis and other related autoimmune disease.

Authors:  Bin Zhang; ShuXiang Pu; BinMei Li; JianRui Ying; Xing Wang Song; Cong Gao
Journal:  Lipids Health Dis       Date:  2010-03-29       Impact factor: 3.876

10.  Plasma levels of apolipoprotein A1 in malaria-exposed primigravidae are associated with severe anemia.

Authors:  David C Simpson; Edward Kabyemela; Atis Muehlenbachs; Yuko Ogata; Theonest K Mutabingwa; Patrick E Duffy; Michal Fried
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.